Muloc, Daelyn C.
HRN: 12-37-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/27/2022
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
07/27/2022
08/03/2022
PO
3.5ml
BID
Multiple Soft Tissue Injuries
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes